Lipocine Inc. Common Stock (LPCN)
Stock · NASDAQ · Health Care
$1.56as of 10/16/2026
Price chart
Active signals
LPCN Signal Track Record
How signals performed across all stocks →What LPCN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -4.8% | 43% | October 1, 2026 |
| Bollinger Band Breakdown | 24 | +0.2% | 50% | October 8, 2026 |
| Bollinger Band Breakout | 25 | -6.0% | 36% | August 26, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +22.0% | 86% | December 5, 2025 |
| Any 20-session window (baseline) | -3.5% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of tes…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 14
- Website
- www.lipocine.com/
Fundamentals
- 1-day range
- $1.5$1.66
- Market cap
- $17.56M
- P/E (trailing)
- —
- P/E (forward)
- -1.23
- EPS (trailing)
- $-1.87
- Dividend yield
- —
- Beta
- 0.41
- Avg. volume
- 1.77M
How Lipocine Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Lipocine Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LPCNLipocine Inc. Common Stock$1.56▼ 7.14%Market cap $17.56MP/E —$1.59$12.37
- CTXRCitius Pharmaceuticals Inc. Common Stock$0.46▲ 0.00%Market cap $17.62MP/E —$0.46$2.19
- NCELNewcelX Ltd. Ordinary Shares$2.5▼ 12.28%Market cap $17.98MP/E —$1.83$18.4
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
- SKYESkye Bioscience Inc. Common Stock$1.55▼ 2.52%Market cap $16.58MP/E —$1.5$13.28
- MRKRMarker Therapeutics Inc. Common Stock$1.04▲ 13.04%Market cap $18.67MP/E —$0.84$2.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LPCN Lipocine Inc. Common Stock | $17.56M | — | $1.56 | ▼ 7.14% | $1.59$12.37 |
| CTXR Citius Pharmaceuticals Inc. Common Stock | $17.62M | — | $0.46 | ▲ 0.00% | $0.46$2.19 |
| NCEL NewcelX Ltd. Ordinary Shares | $17.98M | — | $2.5 | ▼ 12.28% | $1.83$18.4 |
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
| SKYE Skye Bioscience Inc. Common Stock | $16.58M | — | $1.55 | ▼ 2.52% | $1.5$13.28 |
| MRKR Marker Therapeutics Inc. Common Stock | $18.67M | — | $1.04 | ▲ 13.04% | $0.84$2.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here's Why You Should Add LPCN Stock to Your Portfolio NowYahoo · 10/8/2026
- BC-Most Active StocksYahoo · 10/7/2026
- Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement MarketYahoo · 10/7/2026
- Lipocine stock surges 30% on Health Canada drug approvalYahoo · 10/7/2026
- LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar TodayYahoo · 10/7/2026
- Nasdaq Falls Over 100 Points; US Crude Inventories DeclineBenzinga · 10/7/2026
- Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement TherapyYahoo · 10/7/2026
- Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In CanadaBenzinga · 10/7/2026
Insider Activity
Insider Actions →- John W. Higuchi · September 30, 2026 · Buy16.0K @ $2.23
- John W. Higuchi · September 29, 2026 · Buy9.0K @ $2.15
- Michael Grissinger · August 3, 2026 · Grant2.0K @ $2.11
- John W. Higuchi · June 3, 2026 · Grant1.8K @ $2.19
- Jene Jill M. · June 3, 2026 · Grant1.8K @ $2.19
- Richard Dana Ono · June 3, 2026 · Grant1.8K @ $2.19
Institutional Ownership
March 31, 2026
- Total shares held
- 3.08M
- Total value held
- $24.64M
- Institutional holders
- 44
- Unknown508.6K
- Unknown450.0K
- Unknown295.0K
- Unknown221.6K
- Unknown200.7K
- Unknown200.0K
- Unknown160.4K
- Unknown140.5K
- Unknown124.9K
- Unknown111.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Lipocine Partner Verity Gets Health Canada Approval for TLANDO
Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Lipocine Partner Verity Gets Health Canada Approval for TLANDO. Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.